Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 June 2020 | Story Leonie Bolleurs | Photo Supplied
Dr Ehlers was appointed to serve on the National Forensic Oversight and Ethics Board of 10 members for a second term, based on her knowledge in the field of forensic sciences.

Dr Karen Ehlers from the Department of Genetics at the University of the Free State (UFS) was elected as a member of the National Forensic Oversight and Ethics Board (NFOEB) for a second term.

Dr Ehlers has been appointed to the board of 10 members based on her knowledge in the field of forensic sciences. She is currently conducting research focusing on the forensic application of Y-STR markers, the statistical analysis of DNA profiles, and touch DNA.

Making valuable contributions
Her expertise in the field of forensic genetics assists the board – which also handles complaints about alleged violations relating to the abuse of DNA samples and forensic DNA profiles – to oversee the operations of the Forensic Science Laboratory and the National Forensic DNA Database (NFDD). 

“The knowledge I gained from my current research at the UFS has enabled me to make valuable contributions to the board and its recommendations to the Minister of Police,” says Dr Ehlers. 

In her first term as member of the Board – following regular tracking and analysis of reports, the Board noted an increase in the number of outstanding forensic investigative leads – (hits on the National Forensic DNA Database) that were not followed up.

“After we made enquiries, it was determined that the provincial task teams that were to follow up on the leads, were ad hoc structures that lacked the necessary resources. The Board addressed this shortfall by engaging with various stakeholders and helping to establish permanent structures, called Forensic Investigative Units, with dedicated resources – both human and material – to effectively follow up on all forensic DNA investigative leads. The finalised Regulations were published for comment in the Government Gazette on 27 March 2020,” says Dr Ehlers.

Lowering SA crime rate
While serving on this board, she is ensuring that South Africa has a functioning DNA database that contributes to lowering the crime rate in the country. “As a member of the board, I hope to add value to its functioning. I feel that in the future, science will play an even bigger role in crime prevention, detection, and the solving of crimes,” she states.

Dr Ehlers is Programme Director of the Forensic Sciences Programme in the Department of Genetics. She teaches the Crime Scene Management module to second-year students and supervises seven honours, five MSc, and three PhD students. 

Besides her appointment as member of the NFOEB, she values the work she is doing with her students. “The highlight of my career was when my first group of BScHons students in Forensic Genetics graduated and were shortly thereafter appointed by the Forensic Sciences Laboratory as DNA analysts,” she says. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept